Retatrutide, from Soma Corp., is attracting significant attention as a potential therapy for metabolic regulation. This dual-action drug merges the activity of a GLP-1 receptor stimulant and a GIP receptor stimulant, intended to not only promote reduced body fat but also improve underlying metabolic factors. Early human studies have demonstrated… Read More